Working… Menu
Trial record 7 of 18 for:    "Chromosomal Disease" | "Mercaptopurine"

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01724879
Recruitment Status : Completed
First Posted : November 12, 2012
Last Update Posted : February 11, 2016
Information provided by (Responsible Party):
Nicola Goekbuget, Johann Wolfgang Goethe University Hospital

Brief Summary:

The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together with imatinib. It is recommended to propose allogeneic Standard Induction and Consolidation Therapy (SCT) to all eligible patients with a suitable donor and to continue imatinib with or without additional therapy in patients not undergoing SCT.

This protocol is a study for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia in patients aged 18 to 55 years.

The objective of this strategy is to improve the overall results in the treatment of adult ALL with the addition of specific molecules to the common chemotherapeutic schedule.

Condition or disease Intervention/treatment Phase
Philadelphia Positive Acute Lymphoblastic Leukemia Drug: Dasatinib Phase 2

Detailed Description:

In the present study, the potent ABL tyrosine kinase inhibitor, Dasatinib will be added to standard induction and consolidation chemotherapy for the Philadelphia positive chromosome sub-group of ALL patients aged 18 to 55 years.

The Study hypothesis is, that Dasatinib in combination with standard chemotherapy according to GMALL protocol 07/2003 is feasible and induces cytologic and molecular remission rates comparable to chemotherapy in combination with imatinib without increased treatment-related mortality.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Study Start Date : November 2011
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Arm Intervention/treatment
Experimental: Dasatinib and chemotherapy
Dasatinib, QD p.o. administration, day 1 to EOS
Drug: Dasatinib
Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
Other Names:
  • Sprycel (R)
  • BMS-354825

Primary Outcome Measures :
  1. Treatment-related discontinuation of study treatment (Proportion of Patients) [ Time Frame: Day 120 ]

Secondary Outcome Measures :
  1. Molecular complete remission rate (CR) [ Time Frame: Day 120 ]
  2. Hematologic complete remission rate [ Time Frame: Day 120 ]
  3. Grade III and IV txicity by Common Terminology Criteria for Adverse Events Version 3 [ Time Frame: Day 120 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed new diagnosis of Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia
  • Male or female patients aged 18-55 years
  • Not previously treated except for prephase (corticosteroids, cyclophosphamide, single dose VCR will be permitted) therapy during establishment of the diagnosis
  • Signed written inform consent, willingness and ability to comply with all study procedures
  • Molecular detection of BCR-ABL transcripts
  • Willingness of women of child-bearing potential (WOCBP) and male subjects whose sexual partners are WOCBP, to use an effective form of contraception (pearl index < 1%), such as complete sexual abstinence, combined oral contraceptive, hormone IUCD, vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients or male partners during the study and at least 6 months thereafter. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months).
  • Negative pregnancy test for women of child-bearing potential.

Exclusion Criteria:

  • Patients with ECOG status > 2
  • Patients with QTcF > 470 ms
  • Cardiac insufficiency NYHA grade III/IV, LEVF < 50%, myocardial infarction within the past 6 months prior to study
  • Active secondary malignancy requiring treatment
  • Patients with active, uncontrolled bacterial, viral or fungal infection
  • Known infection with HIV, Hepatitis B (except post vaccinal profile) or C
  • Inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional upper limit of normal and total bilirubin > 2 fold the institutional upper limit unless considered to be due to organ involvement by the leukemia
  • Concurrent severe diseases which exclude the administration of therapy
  • Expected non-compliance or inability to understand informed consent
  • Female patients who are pregnant or breast feeding
  • Treatment with other investigational antileukemic agents after informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01724879

Layout table for location information
Robert Bosch Krankenhaus
Stuttgart, Baden-Württemberg, Germany, 70376
Klinikum der Universität Regensburg
Regensburg, Bayern, Germany, 93042
University Hospital of Frankfurt, Medical Dept. II
Frankfurt, Hessen, Germany, 60590
Medizinische Hochschule Hannover
Hannover, Niedersachsen, Germany, 30625
Universitätsklinikum Essen
Essen, NRW, Germany, 45147
Universitätsklinik Münster
Münster, NRW, Germany, 48149
Universitätsklinik Dresden
Dresden, Sachsen, Germany, 01307
Uniklinik Aachen
Aachen, Germany, 52074
Charité Universitätsmedizin Berlin
Berlin, Germany, 13353
University Hospital Düsseldorf
Düsseldorf, Germany, 40225
Universitätsklinikum Göttingen
Göttingen, Germany, 37075
Asklepios Klinik St. Georg
Hamburg, Germany, 20099
Universitätsklinik Köln
Köln, Germany, 50937
Universität Leipzig, José-Carreras-Haus
Leipzig, Germany, 04103
Universitätskliniken Mainz
Mainz, Germany, 55101
Klinikum Mannheim
Mannheim, Germany, 68167
Universitätsklinikum Großhadern
München, Germany, 81377
Klinikum Nürnberg Nord
Nürnberg, Germany, 90419
Klinikum Oldenburg
Oldenburg, Germany, 26133
Universität Rostock
Rostock, Germany, 18055
Medizinische Universitätsklinik Ulm
Ulm, Germany, 89070
Medizinische Poliklinik der Universität Würzburg
Würzburg, Germany, 97070
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Layout table for investigator information
Principal Investigator: Nicola Gökbuget, Johann Wolfgang Goethe University Hospital

Additional Information:
Layout table for additonal information
Responsible Party: Nicola Goekbuget, Dr. med., MD, Johann Wolfgang Goethe University Hospital Identifier: NCT01724879     History of Changes
Other Study ID Numbers: GMALL-PH-01
2010-022854-18 ( EudraCT Number )
First Posted: November 12, 2012    Key Record Dates
Last Update Posted: February 11, 2016
Last Verified: February 2016
Keywords provided by Nicola Goekbuget, Johann Wolfgang Goethe University Hospital:
philadelphia chromosome
acute lymphoblastic leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Chromosome Aberrations
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Philadelphia Chromosome
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Translocation, Genetic
Pathologic Processes
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action